Kyverna Therapeutics, Inc.
KYTX
$7.66
-$0.19-2.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -39.73M | -37.80M | -36.79M | -42.08M | -44.64M |
| Total Depreciation and Amortization | 351.00K | 368.00K | 415.00K | 515.00K | 501.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.17M | 2.18M | 1.90M | 1.39M | 1.40M |
| Change in Net Operating Assets | -5.39M | 1.73M | -8.85M | 8.23M | -2.18M |
| Cash from Operations | -41.60M | -33.53M | -43.32M | -31.95M | -44.92M |
| Capital Expenditure | -- | 1.00K | -2.00K | -4.00K | -- |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 70.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.20M | -17.29M | 22.49M | 29.17M | 5.58M |
| Cash from Investing | -50.20M | -17.29M | 22.56M | 29.17M | 5.58M |
| Total Debt Issued | -- | 24.70M | -- | -- | -- |
| Total Debt Repaid | -86.00K | -85.00K | -120.00K | -262.00K | -341.00K |
| Issuance of Common Stock | 243.00K | 116.24M | 1.65M | 0.00 | 3.00K |
| Repurchase of Common Stock | -189.00K | -50.00K | -43.00K | -51.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -69.00K | -63.00K | 0.00 | -336.00K | -76.00K |
| Cash from Financing | -101.00K | 140.74M | 1.49M | -649.00K | -414.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.90M | 89.93M | -19.28M | -3.43M | -39.75M |